Download Final Program - Society for Immunotherapy of Cancer
Download Final Program - Society for Immunotherapy of Cancer
Download Final Program - Society for Immunotherapy of Cancer
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Program</strong> ScheduleFriday, October 31, 2008 (continued)3:15 PM - 4:45 PM Concurrent Session I: TH-17, Cytokines and T Cell Subsets Cali<strong>for</strong>nia B-CCo-Chairs: Martin Oft - Schering-Plough Biopharma (<strong>for</strong>merly DNAX)Hideaki Tahara, MD, PhD - University <strong>of</strong> Tokyo3:15 PM - 3:40 PM IL-23 Promotes Tumor Associated Inflammation and SubvertsImmune SurveillanceMartin OftSchering-Plough Biopharma (<strong>for</strong>merly DNAX)3:40 PM - 4:05 PM Potent Anti-Tumor Immunity and Both TH-1 and TH-17 PromotionAssociated with IL-23 AdministrationHideaki Tahara, MD, PhDUniversity <strong>of</strong> Tokyo4:05 PM - 4:30 PM TH-17 Cells in Ovarian <strong>Cancer</strong> PatientsIlona Kryczek, PhDUniversity <strong>of</strong> Michigan4:30 PM - 4:45 PM CD40 Dependent Induction <strong>of</strong> TH-17 Effector Cells from TRegulatory Cells Using the Immune Modulator B7-DC XAbSuresh Radhakrishnan, PhDMayo Clinic, College <strong>of</strong> Medicine3:15 PM - 4:45 PM Concurrent Session II: Endpoints, Response Criteria <strong>for</strong> Plaza RoomClinical Trial DesignCo-Chairs: Thomas A. Davis, MD - Celldex Therapeutics, Inc.Jeffrey Schlom, PhD - National <strong>Cancer</strong> Institute, NIH3:15 PM - 3:35 PM Immunotherapies in Combination with Other TherapeuticModalities: New Paradigms <strong>for</strong> Clinical Trial DesignJeffrey Schlom, PhDNational <strong>Cancer</strong> Institute, NIH3:35 PM - 3:50 PM Overall Survival and New Patterns <strong>of</strong> Response in Patients withAdvanced Melanoma Treated with IpilimumabSteven J. O’Day, MDThe Angeles Clinic and Research Institute3:50 PM - 4:05 PM Identification <strong>of</strong> Antibody Responses Induced in Patients withCastration-Resistant Prostate <strong>Cancer</strong> Receiving GVAX <strong>Immunotherapy</strong><strong>for</strong> Prostate <strong>Cancer</strong>Karin Jooss, PhDCell Genesys, Inc.4:05 PM - 4:25 PM Endpoints <strong>for</strong> Biologic Therapeutics in OncologyPeter Bross, MDFDA- Office <strong>of</strong> Cellular, Tissue, and Gene Therapies4:25 PM - 4:45 PM Panel Discussion5:00 PM - 5:30 PM iSBTc Membership Business Meeting Cali<strong>for</strong>nia B-C(iSBTc Members Only)5:30 PM - 7:30 PM Reception with Poster Viewing Garden Pavilion, 4th Floor18
Change language